What patients don't say

As a neurologist in a busy clinic, I spend my days decoding the body's quiet rebellions: the tremor that betrays dopamine's decline, the rigidity that transforms fluid movement into effort. But some of the most consequential complications of treatment are not visible on examination. Most visits follow a familiar rhythm: medications adjusted, symptoms measured, progress noted. Yet one patient's hesitant confession unsettled that routine and forced me to confront something medicine often overlooks. The drugs we prescribe to restore control can also unravel it, producing a shame so profound that patients suffer in silence while lives fracture quietly. We are trained to look for tremor, rigidity, and bradykinesia. We count finger taps, measure stride length, and assess tone. Nevertheless, some of the most devastating complications of Parkinson's disease treatment do not announce themselves on neurological examination. They hide in behaviors patients are reluctant to name, and clinicians are not always prepared to ask about. Mr. D came to the clinic with worsening tremor and visible anxiety. His examination suggested agitation rather than disease progression. There was no meaningful change in gait, tone, or speed of movement. Yet his worsened tremor and his posture, with downcast eyes, shoulders drawn inward, suggested he was carrying something heavier than motor symptoms. When I paused and gave him space to speak, he said quietly, “Doctor, I need to stop.” “Stop what?” I asked. “The fishing,” he said. “I can't stop fishing.” He could not meet my eyes. What followed was not a casual mention of a hobby, but a confession offered with palpable humiliation. Over 18 months, a weekend pastime had become an obsession. He spent hours each day online buying fishing equipment he did not need. He opened a secret credit card to pay for it. He fished compulsively, regardless of weather, work obligations, or family conflict. He knew the behavior was destructive, yet felt powerless to resist it. By the time he told me, his finances were strained and his wife had left. “I'm so ashamed,” he said. “I felt like I was going crazy. But I was too embarrassed to tell anyone.” The cause was not psychological weakness or moral failure. Mr. D had been taking pramipexole, a dopamine agonist, for 2 years. Dopamine agonists are effective treatments for Parkinson's motor symptoms, but they also stimulate brain circuits involved in reward and motivation. In susceptible patients, this stimulation can transform ordinary activities into irresistible compulsions. Impulse control disorders (i.e., pathological gambling, compulsive shopping, binge eating, hypersexuality, and obsessive engagement with hobbies) affect a substantial proportion of patients treated with dopamine agonists. Estimates range from 14% to 40%, depending on population and methodology.1 However, despite their frequency, these disorders remain under-recognized in routine clinical care. One reason is shame. Across medicine, shame is among the most powerful barriers to disclosure during clinical encounters. Side effects that affect behavior, self-control, or social identity are particularly difficult to report. They are not merely uncomfortable. They strike at the core of who patients believe they are. Mr. D lived with what has been described as shame anxiety, the chronic anticipation of humiliating exposure.2 Each day carried the fear that someone would discover his secret. Each interaction felt like a potential moment of judgment. Concealment required constant vigilance. He did not deceive me outright; he simply remained silent. This pattern is not unique to Parkinson's disease. Patients who feel ashamed of side effects are more likely to minimize symptoms, skip appointments, alter medications without consultation, or disengage from care altogether, even when they understand that the treatment itself is beneficial. In studies of severe mental illness, distress related to medication side effects is common, with embarrassment ranking among the most burdensome experiences.3 Similar patterns appear across chronic disease: children hide inhaler use at school,4 patients delay seeking care for stigmatized conditions, and individuals omit medications to avoid socially visible effects. For Mr. D, the compulsive fishing felt like evidence of personal failure. He interpreted it as a lack of willpower or integrity, not as a predictable consequence of how medication was affecting his brain's reward circuitry. That distinction mattered. Without a medical framework, shame filled the explanatory gap. The nature of impulse control disorders compounds this silence. The behaviors most commonly involved—gambling, spending, sexual behavior, and eating—are already socially stigmatized. These are precisely the experiences patients are least likely to volunteer, and clinicians are least comfortable asking about without an explicit opening. Shame also alters behavior in ways that directly harm health. Patients who anticipate judgment are more likely to withdraw from care or make decisions in isolation. By the time impulse control disorders are recognized, damage is often already done. Relationships fracture. Financial losses accumulate. Trust erodes. The behaviors themselves may be reversible; their consequences often are not. Mr. D's silence was understandable. The more difficult question was what systems existed to detect this complication before it dismantled his life. The answer was uncomfortable: very few. Clinical guidelines acknowledge impulse control disorders, but systematic screening is rarely mandated. Time pressures in busy clinics discourage comprehensive behavioral assessments. General questions like “How are you doing?” or “Any problems with your medications?” are insufficient for symptoms that patients feel ashamed to disclose. This is not a failure of individual clinicians, but of system design. When detection depends on spontaneous disclosure, conditions rooted in shame predictably remain hidden. Clinical encounters, despite good intentions, can inadvertently intensify shame. The asymmetry of the patient–physician relationship, the inherent exposure of the examination, and the pressure to appear “coping” all make disclosure feel risky. Mr. D had no trouble describing tremor or stiffness. He struggled to name something that felt humiliating. When he finally did, his body spoke first: a lowered voice, an averted gaze, a long pause before words emerged. These are not signs of evasion. They are the physical language of shame. What made disclosure possible was not a checklist, but permission. When behaviors are framed as known medication effects rather than personal failings, patients are more able to speak. Direct questions, asked neutrally, without surprise, can reduce shame rather than provoke it. When Mr. D asked whether the problem could be fixed, my answer was cautiously reassuring. Dopamine agonist–induced impulse control disorders are often reversible with dose reduction or discontinuation, provided tapering is gradual. We reduced his pramipexole while adjusting levodopa. Within weeks, the compulsive behavior resolved. His enjoyment of fishing returned to what it had once been. The marriage did not. That asymmetry between how reversible the behavior can be and how lasting the consequences may become has stayed with me. Since then, I screen every patient taking dopamine agonists at every visit. I ask directly about gambling, shopping, eating, sexual behavior, and hobbies. I frame these changes explicitly as medication effects, not character flaws. Specificity matters. General questions about mood or coping will not uncover experiences patients are ashamed to name. Validated tools, such as brief questionnaires for impulse control disorders, make systematic screening feasible even in busy practices.5 Since incorporating routine screening, I have identified patients with early signs of compulsive behaviors often before serious harm occurred. Early recognition allows intervention while consequences are still preventable. Mr. D's story is not only about Parkinson's disease. It is about how medicine confronts side effects that injure dignity as much as physiology. In hospital medicine, where acute exacerbations often reveal gaps in chronic outpatient management, undisclosed side effects can prolong admissions, trigger readmissions, or complicate inpatient care. Treatments can restore function and still impose hidden psychological costs. When shame goes unrecognized, it becomes an invisible adverse effect, one that distorts care long after prescriptions are written. If we want patients to tell us what matters most, we must make room for what is hardest to say. The most important clinical signs do not always appear on examination. Sometimes they surface as downcast eyes, a lowered voice, or a pause before answering. These are not moments to rush past. They are signals. Shame is quiet. Its consequences are not. If we do not ask—directly, routinely, and without judgment—it will continue to do its work in silence, we help create. The author has no funding to report. The author declares no conflict of interest. Patient identifying details have been modified to protect confidentiality while preserving complete clinical accuracy. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.